These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 25124236)

  • 1. The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention.
    Siller-Matula JM; Gruber C; Francesconi M; Dechant C; Jilma B; Delle-Karth G; Grohs K; Podczeck-Schweighofer A; Christ G
    Clin Sci (Lond); 2015 Jan; 128(2):121-30. PubMed ID: 25124236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study.
    Siller-Matula JM; Francesconi M; Dechant C; Jilma B; Maurer G; Delle-Karth G; Gouya G; Ruzicka K; Podczeck-Schweighofer A; Christ G
    Int J Cardiol; 2013 Sep; 167(5):2018-23. PubMed ID: 22656044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
    Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ
    J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response--the TAILOR (Thrombocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial.
    Dridi NP; Johansson PI; Clemmensen P; Stissing T; Radu MD; Qayyum A; Pedersen F; Helqvist S; Saunamäki K; Kelbæk H; Jørgensen E; Engstrøm T; Holmvang L
    Platelets; 2014; 25(7):506-12. PubMed ID: 24245960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).
    Cuisset T; Grosdidier C; Loundou AD; Quilici J; Loosveld M; Camoin L; Pankert M; Beguin S; Lambert M; Morange PE; Bonnet JL; Alessi MC
    JACC Cardiovasc Interv; 2013 Aug; 6(8):854-63. PubMed ID: 23968703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
    Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
    J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.
    Mayer K; Schulz S; Bernlochner I; Morath T; Braun S; Hausleiter J; Massberg S; Schunkert H; Laugwitz KL; Kastrati A; Sibbing D
    Thromb Haemost; 2014 Aug; 112(2):342-51. PubMed ID: 24718389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of platelet reactivity monitoring-adjusted clopidogrel therapy versus prasugrel therapy to reduce high on-treatment platelet reactivity.
    Bonello L; Laine M; Baumstarck K; Fernandez J; Maillard L; Peyrol M; Bessereau J; Aradi D; Camilleri E; Roubille F; Piot C; Paganelli F; Camoin-Jau L; Dignat-George F
    Int J Cardiol; 2013 Oct; 168(4):4244-8. PubMed ID: 23911273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the degree of platelet aggregation inhibition with prasugrel versus clopidogrel and clinical outcomes in patients with unprotected left main disease treated with everolimus-eluting stents.
    Migliorini A; Valenti R; Parodi G; Marcucci R; Abbate R; Carrabba N; Gensini GF; Antoniucci D
    Am J Cardiol; 2013 Dec; 112(12):1843-8. PubMed ID: 24063827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention.
    Yokoi H; Kimura T; Isshiki T; Ogawa H; Ikeda Y
    Thromb Res; 2012 May; 129(5):623-8. PubMed ID: 22178576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevation acute coronary syndrome.
    Paarup Dridi N; Johansson PI; Lønborg JT; Clemmensen P; Radu MD; Qayyum A; Pedersen F; Kollslid R; Helqvist S; Saunamäki K; Kelbæk H; Jørgensen E; Engstrøm T; Holmvang L
    Platelets; 2015; 26(6):521-9. PubMed ID: 25166751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
    Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
    Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
    Aradi D; Tornyos A; Pintér T; Vorobcsuk A; Kónyi A; Faluközy J; Veress G; Magyari B; Horváth IG; Komócsi A
    J Am Coll Cardiol; 2014 Mar; 63(11):1061-70. PubMed ID: 24486281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
    Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
    JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Dasbiswas A; Rao MS; Babu PR; Vijayvergiya R; Nayak R; Dani S; Tyagi S; Hiremath S; Patel T; Alexander T; Prakash VS; Singh DP; Yadav MK; Pathak K; Srivastava A
    J Assoc Physicians India; 2013 Feb; 61(2):114-6, 126. PubMed ID: 24471250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention.
    Park DW; Ahn JM; Song HG; Lee JY; Kim WJ; Kang SJ; Yun SC; Lee SW; Kim YH; Lee CW; Park SW; Park SJ
    Am Heart J; 2013 Jan; 165(1):34-42.e1. PubMed ID: 23237131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial.
    Park JB; Koo BK; Choi WG; Kim SY; Park J; Kwan J; Park CG; Kim HS
    Clin Ther; 2013 Jan; 35(1):28-37.e4. PubMed ID: 23328268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New antiplatelet agents in the treatment of acute coronary syndromes.
    Sabouret P; Taiel-Sartral M
    Arch Cardiovasc Dis; 2014 Mar; 107(3):178-87. PubMed ID: 24630752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
    Sibbing D; Braun S; Morath T; Mehilli J; Vogt W; Schömig A; Kastrati A; von Beckerath N
    J Am Coll Cardiol; 2009 Mar; 53(10):849-56. PubMed ID: 19264241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.